Cannone Valentina, Ledwidge Mark, Watson Chris, McKie Paul M, Burnett John C, McDonald Kenneth
Cardiorenal Research Laboratory, Division of Circulatory Failure, Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota, USA.
Department of Medicine and Surgery, University of Parma, Parma, Italy.
JACC Basic Transl Sci. 2021 Jun 16;6(6):497-504. doi: 10.1016/j.jacbts.2021.05.001. eCollection 2021 Jun.
B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.
B型利钠肽（BNP）具有降低血压、抗纤维化和抑制醛固酮的特性。在A期和B期心力衰竭患者中，BNP基因变异rs198389的次要C等位基因携带者的BNP循环水平较高，发生高血压、新发左心室收缩功能障碍以及因主要不良心血管事件住院的风险降低。有必要开展进一步研究，以探究BNP基因检测和基于BNP的治疗在心力衰竭预防中的作用。
